Aprea Therapeutics, Inc.

APRE
$0.75 (+ $0.02 + 2.15%)
Last updated: 2026-06-10 22:06 UTC
APRE Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS03836J1025
CUSIP03836J102
Market Price0.75
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-2.12
Market Cap$6.7M
Book Value1.82
Price to Book0.521
Beta1.57
52w High5.0
52w Low0.9
Next Earnings DateN/A

Aprea Therapeutics, Inc. trades under ticker APRE on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US03836J1025, CUSIP 03836J102. Also searched as Aprea Therapeutics.

Related researchAPRE stock priceAPRE share priceAprea Therapeutics stockAprea Therapeutics share price03836J102
About the Company
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Price History